Artelo Biosciences
ARTL
5 hedge funds and large institutions have $75.8K invested in Artelo Biosciences in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
107% more capital invested
Capital invested by funds: $36.6K → $75.8K (+$39.2K)
67% more funds holding
Funds holding: 3 → 5 (+2)
1.57% more ownership
Funds ownership: 1.07% → 2.64% (+1.6%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$25.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$543 |
ARTL Hedge Fund Activity: Q1 2025 in Review
5 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2025, worth a combined $75.8K — up 107% from $36.6K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ARTL positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $25.3K. The largest seller was UBS Group, cutting an estimated $543.
- 5 institutional investors held Artelo Biosciences (ARTL) as of Q1 2025, up from 3 in Q4 2024.
- Funds reported $75.8K of Artelo Biosciences stock for Q1 2025, up 107% quarter-over-quarter.
- 2 funds opened new Artelo Biosciences positions in Q1 2025 and 0 closed out, a net change of +2 holders.
- The largest Artelo Biosciences buyer in Q1 2025 was Citadel Advisors, an estimated $25.3K added.
- The largest Artelo Biosciences seller in Q1 2025 was UBS Group, an estimated $543 sold.
Based on aggregated 13F filings for Q1 2025.